

# Relating compound toxicity to molecular structure using machine learning

Master Thesis
Robin Bosshard, 16-915-399
October 16, 2023

Supervisors: Prof. Dr. Fernando Perez-Cruz, Dr. Eliza Harris, Lili Gasser (SDSC)
Dr. Kasia Arturi (Eawag)

Department of Computer Science, ETH Zürich

#### **Abstract**

Abstract goes here.

#### Acknowledgments

First and foremost, I would like to thank Prof. Dr. Fernando Perez-Cruz from the Swiss Data Science Center (SDSC) for providing me the opportunity of working on this fascinating project. His continued support is very appreciated.

I would like to express my sincere gratitude to my supervisor Dr. Kasia Arturi from Swiss Federal Institute of Aquatic Science and Technology (Eawag) and my supervisors Dr. Eliza Harris, Lili Gasser from SDSC for the many discussions and valuable insights. Without their help, this thesis would not have been possible.

Furthermore, I extend my gratitude to Jason Brown, Feshuk Madison, and Katie Paul Friedman for engaging in discussions regarding technical aspects of the tcpl pipeline and the ToxCast database.

Lastly, my special thank goes to my family and friends for their unconditional support throughout my studies.

# Contents

C	onten	ts		ii			
1	Introduction						
_	1.1		hallenge of Environmental Pollution	1 1			
	1.2		mperative for Prioritization and Toxicity Assessment	2			
	1.3		romise of Machine Learning in Toxicity Prediction	3			
	1.4		vitroTox: A Novel Approach	3			
	1.5		* *	3			
			tives and Significance	4			
	1.6	mesis	structure	4			
2	Literature Review						
	2.1	Backg	round	5			
	2.2		xt	5			
3	Mat	erial ar	nd Methods	6			
	3.1 Invitrodb						
	0.1	3.1.1	Data Overview	6 6			
	3.2	•	1	9			
	0.2	3.2.1	Pipeline	10			
		3.2.2	Curve Surfer	10			
	3.3 Machine Learning Pipeline						
	0.0	3.3.1	Preprocessing	10 10			
		3.3.2	Binary Classification	11			
		3.3.3	Regression	11			
		3.3.4	Massbank Validation	11			
		3.3.4	Wassbank validation	11			
4	Results and Discussion						
5	Conclusion						
Bi	Bibliography						

		Contents
A	Appendix	16

## Introduction

## 1.1 The Challenge of Environmental Pollution


Over the past few decades, the upsurge in environmental pollution by chemical compounds has been driven by industrial processes, agricultural methods, our consumerism and various other contributing factors. This has resulted in significant ecological and health issues. Although these chemicals are integral for many products and have the potential to improve our comfort of modern society, they can also pose risks and adversely affect both our health and the environment, either acutely or chronically. Toxic substances threaten wildlife but also makes our air, soil and finally our drinking water and food supply less safe. The EU currently maintains comprehensive chemical regulations, however, it is anticipated that global chemicals production will double by 2030 [1]. Moreover, the widespread utilization of chemicals, including their inclusion in consumer goods, is expected to expand further. Even though there are over 275 million known chemical compounds registered by the Chemical Abstracts Service (CAS) [2], merely a tiny fraction of them undergo close monitoring via target analytical approaches and even less is known about their toxicity profiles and negative health effects on our organsims.

Building upon the European Green Deal [3], the 8th Environment Action Programme, guiding European environmental policy until 2030, reinforces the EU's goal of sustainable living within planetary limits, with a vision extending to 2050. One of its key objectives is a zero-pollution commitment, covering air, water, and soil, prioritizing the well-being of EU citizens. In particular, the European Commission published a sustainability-focused chemicals strategy (CSS), aligning with the EU's zero-pollution ambition with one of the objectives to minimize concerning substances by either substituting or phasing them out wherever feasible [4]. Consequently, the urgent need to monitor and effectively assess the hazards associated with the daily entering of thousands of poorly understood chemicals into our

environment becomes increasingly evident.

# 1.2 The Imperative for Prioritization and Toxicity Assessment

Modern analytical methods, especially high-resolution mass spectrometry (HRMS/MS), are becoming increasingly important in fields like metabolomics, drug discover, forensics and environmental science and toxicology. Nontarget HRMS/MS has improved the ability to detect emerging compounds in environmental samples, often with unknown toxicity profiles. These compounds are assessed based on factors such as abundance and fragmentation data. See in Figure 1.1 for an overview. However, the endeavor to identify compounds and characterize their toxicity remains a resource-intensive and time-consuming process. This challenge is further impeded by the scarcity of well-characterized substances that can be used as references for comparison when analyzing unknown compounds, hindering comprehensive elucidation. Traditionally, the prioritization of unidentified compounds rely on signal intensity as a guiding metric. Unfortunately, this approach falls short in delivering an accurate assessment of environmental exposures, as it tends to overlook the crucial toxicological dimension. Consequently, substances with the potential for severe ecological consequences, such as endocrine-disrupting compounds, frequently evade detection due to their low abundance, despite their high toxicity. Therefore, there is an urgent need for alternative prioritization strategies that incorporate the toxicity and ecological impact more effectively.



**Figure 1.1:** Figure 1 adapted (with modified Prioritization step) from Hollender et al. [5]: Nontarget screening with high resolution mass spectrometry in the environment: Ready to go?

## 1.3 The Promise of Machine Learning in Toxicity Prediction

In the past few years, machine learning has emerged as a transformative force in the field of toxicology, particularly in the realm of high-throughput toxicity prediction. High-throughput screening (HTS) has revolutionized the way we assess toxicity by allowing thousands of in vitro bioassays to be conducted rapidly. This high-throughput approach, coupled with advancements in robotics and automated analysis, has generated large volumes of toxicity data, paving the way for more comprehensive assessments of chemical compounds. Alongside the rise of machine learning, this advancement has facilitated the creation of predictive models capable of forecasting compound toxicity based on their chemical structure. These models can be trained on extensive datasets containing well-documented toxicity information, allowing them to learn the underlying patterns and relationships between chemical structure and target toxicity. Once trained, these models can reliably predict the toxicity of new compounds, even if they have not undergone laboratory testing. This approach holds the potential to significantly reduce the time and cost associated with early-stage toxicity pre-assessment and plays a crucial role in prioritizing compounds for further in-depth testing.

## 1.4 MLinvitroTox: A Novel Approach

In response to the pressing need for a more efficient and comprehensive assessment of environmental contaminants, MLinvitroTox [6], an innovative machine learning framework was introduced. MLinvitroTox leverages molecular fingerprints extracted from fragmentation spectra (MS2), marking a fundamental shift in how we forecast the toxicity of the myriad unidentified HRMS/MS features. The framework leverages streamlined machine learning techniques to predict the compounds bioactivity in numerous toxicity endpoints. The toxicity database encompasses nearly 300 target-specific and 90 cytotoxic endpoints sourced from ToxCast/Tox21 data.

## 1.5 Objectives and Significance

The central objective of this thesis is to develop a streamlined framework for the prediction of compound toxicity across multiple endpoints, resulting in the creation of toxicity fingerprint. The generated toxicity fingerprints will provide valuable insights for the prioritization process in identifying most hazardous compounds found in environmental samples, ultimately contributing to the preservation of ecosystems and our health. Notably, the use of SIRIUS molecular fingerprints and xgboost (Extreme Gradient Boosting) models, complemented by feature selection?, has yielded consis-

tently successful results. Furthermore, we have validated the effectiveness of MLinvitroTox by applying it to MassBank spectra, demonstrating an average balanced accuracy of 0.75? in predicting toxicity.

### 1.6 Thesis Structure

In the upcoming chapters, we will explore the methodology and technical aspects associated with the preparation of ToxCast/Tox21 toxicity data, transforming them into appropriate inputs for our machine learning pipeline. This foundational work will set the stage for us, in the subsequent chapters, to unveil the potential of MLinvitroTox. We will also demonstrate the framework's effectiveness through validation using real-world data and discuss about the implications of our research.

## Literature Review

## 2.1 Background

#### 2.2 Context

In their systematic investigation using Tox21 data, Wu et al. (2021) explored the impact of various modeling approaches and chemical features on predictive toxicology, with a focus on model performance and explainability trade-offs. The study found that the assay endpoint from the Tox21 data being predicted was the most significant factor influencing model performance. Endpoints with higher predictability, characterized by lower data imbalance and larger datasets, performed well regardless of the modeling approach or molecular representation. For less predictable endpoints, simpler models like Linear Regression performed similarly to complex ones, prioritizing both predictivity and interpretability. Moreover this study suggests consensus modeling and multi-task learning to enhance predictability and model performance across endpoints. In this thesis, we set the goal to not overlook simpler models due to their higher interpretability and comparable performance. As suggested we do not further investigate on the differnt molecular representations and use a fixed compilation of molecular fingerprints (Sirius) as initial input features. We incorporated in our studies a form of consensus modeling to consolidate predictability and multi-task learning to improve model performance across different endpoints.

## Material and Methods


## 3.1 Invitrodb

The most recent release of the ToxCast's (Toxicity Forecaster) database, referred to as invitroDBv3.5, serves as a source of an extensive collection of high-throughput screening (HTS) targeted bioactivity data. This database encompasses information on a total of 9541 compounds, selectively screened across 2205 assay endpoints. This resource originated from the collaboration of two prominent institutions: the United States Environmental Protection Agency (EPA) through its ToxCast program and the National Institutes of Health (NIH) via the Tox21 initiative. Incorporating data collected from diverse research laboratories, this relational database is openly accessible to the public and can be downloaded directly from the official ToxCast website.

#### 3.1.1 Data Overview

#### **Presence Matrix**

Consider a collection of m assay endpoints, denoted by  $A = \{a_1, a_2, \ldots, a_m\}$  and a set of n compounds represented as  $C = \{c_1, c_2, \ldots, c_n\}$ . To facilitate data comprehension, we introduce a *presence matrix*  $P \in \{0,1\}^{m \times n}$ . Rows, indexed by i, represent assay endpoints  $a_i$ , while columns, indexed by j, denote presence (1) or absence (0) of compound  $c_j$  in those endpoints. Matrix P is sparse due to the selective testing of compounds across different assay endpoints. A compound is considered present in an assay endpoint if it has undergone testing and a corresponding concentration-response series is available. See Figure 3.1 for a visual of the *presence matrix* P covering all assay endpoints and compounds in *invitroDBv3.5*.



**Figure 3.1:** The presence matrix P covering all assay endpoints and compounds available in invitroDBv3.5 with m=2205 assay endpoints and n=9541 compounds. The presence matrix is organized by sorting it based on the number of compounds present in each assay endpoint and the compounds are arranged in descending order of their presence frequency. The total count, where  $P_{ij}=1$ , indicates the availability of  $3\,342\,377$  concentration-response series for downstream analysis.

#### Subsetting data


We exclusively consider assay endpoints that have been tested with a minimum of 2000 compounds. This criterion ensures the availability of sufficient data for the training of a machine learning model. Refer to Figure 3.2 for a visual representation of the *presence matrix P*, which now encompasses only the resulting subset of all assay endpoints within *invitroDBv3.5*. From now on, we will call this specific subset the data that we will be focusing on for this thesis.

#### **Concentration-Response Series**

A *concentration-response series* is represented as a set of k concentration-response pairs:

$$S = \{(conc_1, resp_1), (conc_2, resp_2), \dots, (conc_k, resp_k)\}$$

For each entry in the presence matrix P with  $P_{ij} = 1$ , we collect the corresponding concentration-response series  $S_{ij}$  for the compound  $c_j$  in the assay endpoint  $a_i$ . We analyse in total  $\sum_{i,j} P_{ij} = 1\,372\,225$  concentration-response series, comprising a sum of  $\sum_{i,j} |S_{ij}| = 48\,861\,036$  concentration-response pairs across all compounds and assay endpoints. We get the concentration-response pairs by combining tables mc0, mc1, and mc3 from invitroDBv3.5. We also gather necessary sample information such as well type, row, and



**Figure 3.2:** The *presence matrix* P covering only the subset of all of assay endpoints available in *invitroDBv3.5*, considered for this thesis, encompassing m=271 assay endpoints and n=9456 compounds. The total count, where  $P_{ij}=1$ , indicates the availability of  $1\,372\,225$  concentration-response series for downstream analysis.

column index from the assay well-plate. The concentrations are transformed to the logarithmic scale using the unit  $\mu M$  (micromolar), while the responses are normalized to either fold-induction or percent-of-control units. Figure 3.3 showcases a single concentration-response series for some compound tested within an assay endpoint.



**Figure 3.3:** A concentration-response series for the compound *Estropipate* (DTXSID3023005) in the assay endpoint  $TOX21\_ERa\_LUC\_VM7\_Agonist$  (aeid=788). The series has a total of k=45 concentration-response pairs and is composed of  $n_{conc}=15$  concentration groups, each with  $n_{rep}=3$  replicates.

In this section, we demonstrate the significance of variations in concentration-

response pairs among different compounds and assay endpoints. In practice, concentrations are often subjected to multiple testing iterations, resulting in the formation of distinct concentration groups. Within each concentration group, the number of replicates is indicated by  $n_{rep}$ . We introduce the following quantities corresponding to a concentration-response series for a compound  $c_i$  in a given assay endpoint  $a_i$ :

- $n_{\text{datapoints}_{i,i}}$ : the total number of concentration-response pairs (|S|)
- n<sub>groups<sub>i</sub></sub>: the number of distinct concentrations tested

Concentration metrics averaged across all concentration-response series aggregated by Assay Endpoint & Compound Index

- $n_{\text{replicates}_{i,i}}$ : the number of replicates for each concentration group
- $min_{conc_{i,i}}$ : the lowest concentration tested
- *max*<sub>conc<sub>i,i</sub>: the highest concentration tested</sub>

For an overview of these quantities across the entire set of considered concentration-response series, please refer to Figure 3.4. This figure illustrates the above metrics aggregated by their means, grouped by assay endpoints and compounds.

Aggregated By:

Assay Endpoin

Compound

Aggregated By:

Assay Endpoin

Compound

**Figure 3.4:** Concentration metrics averaged across all concentration-response series aggregated by assay endpoint (blue) and compound (orange). E.g., the first chart shows the distribution on the average number of datapoints across all assay enpoint  $a_i \in A$  with  $\frac{1}{|C|} \sum_j n_{\text{datapoints}_{i,j}}$  and across all compounds  $c_j \in C$  with  $\frac{1}{|A|} \sum_i n_{\text{datapoints}_{i,j}}$ . The same is done for the other metrics:  $n_{\text{groups}_{i,j}}$ ,  $n_{\text{replicates}_{i,j}}$ ,  $min_{\text{conc}_{i,j}}$ , and  $max_{\text{conc}_{i,j}}$ .

## 3.2 Pytcpl

We introduce pytcpl, a streamlined Python package inspired by the R package tcpl, designed for processing high-throughput screening data. The package primarily focuses on providing essential features such as concentration-response curve fitting and allows for continuous hit-calling for compound bioactivity across diverse assay endpoints, akin to tcplfit2. Invitrodb version 3.5 release can optionally serve as backend database if desired. The package optimizes data storage and provides compressed raw data and metadata from <code>invitroDB</code> in Parquet files. This efficient strategy reduces storage needs,

resulting in just 4 GB within the repository—compared to the original 80 GB database. This obviates the need for a cumbersome, large-scale database installation, rendering downstream analysis more accessible and efficient. Our package is crafted to accomodate cusomizable processing steps and facilitate interactive data visualization with curve surfer. Moreover, it empowers Python-oriented researchers to seamlessly engage in data analysis and exploration.

#### 3.2.1 Pipeline

- 1. Data collection
- 2. Cutoff determination and filtering (Meet conditions for curve fitting)
- 3. Curve fitting
- 4. Hit calling

#### **Data Collection**

First, all datapoints are collected from the database and assigned to the concentration response-series belonging to the respective compound in the corresponding assay endpoint.

#### **Curve Fitting**

Introduce all candidate fit models, discuss the pros and cons of each model. Discuss the fitting procedure, how the models are fitted, Maximum Likelihood Estimation

#### Hit Calling

Akaike criterion, probability of being active, etc..

#### 3.2.2 Curve Surfer

Data visualization, overview of what is possible with the tool. Filter by assay endpoint, compound, etc.

## 3.3 Machine Learning Pipeline

#### 3.3.1 Preprocessing

Subselecting the columns from the output tables generated by pytcpl: DTXSID identifier and continuous hitcall value. The feature inputs to the machine learning model is a molecular structure represented as fingerprint generated from a SMILES string uniquely determined by the compounds DTXSID

identifier. The SMILES string is a linear representation of a compound's molecular structure. The SMILES string is converted to a molecular graph, which is then converted to a feature vector. The feature vector is then used to train a machine learning model. The machine learning model is then used to predict the hitcall value for a given compound. The machine learning pipeline is illustrated in Figure ??.

#### 3.3.2 Binary Classification

The goal is to predict whether a compound is active or inactive for a given assay endpoint. We can formulate this as a binary classification problem, where the input is the compound's molecular structure fingerprint and the output is the hitcall value binarized by some decision threshold. The hitcall value is rendered to a binary variable, where 1 indicates that the compound is active and 0 indicates that the compound is inactive.

#### 3.3.3 Regression

#### 3.3.4 Massbank Validation

# **Results and Discussion**

sectionResults sectionEvaluation sectionDiscussion

## **Conclusion**

We have evidence of a multitude of chemicals being present in the environment and in our bodies and that mixture exposure indeed matters. This knowledge needs to be deepened, and the quantitative contribution of chemicals to compromised health should be better described and translated into regulatory action. As indicated in a scientific opinion paper of the German Federal Environmental Agency (Conrad et al. 2021), the CSS goals may be considered as a moving target. For increasing scientific evidence and improved method for detection and assessment of chemicals, development of new technologies require innovative regulatory, technological and societal reactions. We should be flexible and prepared to take up the scientific challenges and collaborate productively with regulatory institutions to address the identified challenges and modernise chemical risk assessment. This is also in line with the concern of many scientists that chemical pollution and the wide range of adverse effects on human and ecosystem health demand additional efforts on a global scale (Brack et al. 2022; Wang et al. 2021). We see the CSS as a European strategy that, in concert with other initiatives, may open new opportunities to minimise hazardous chemical pollution and thus risks to human health and ecosystems.

## **Bibliography**

- [1] U. N. E. Programme, Global chemicals outlook ii from legacies to innovative solutions: Implementing the 2030 agenda for sustainable development synthesis report, 2019. [Online]. Available: https://wedocs.unep.org/20.500.11822/27651.
- [2] C. A. Service, *Chemical abstracts service (cas) is a division of the american chemical society*, Source of chemical information located in Columbus, Ohio, United States, https://www.cas.org/support/documentation/casdatabases, 2023.
- [3] E. Commission, D.-G. for Research, and Innovation, *European Green Deal Research & innovation call*. Publications Office of the European Union, 2021. DOI: 10.2777/33415.
- [4] E. Commission, "Eu chemicals strategy for sustainability towards a toxic-free environment," 2020, Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions Chemicals Strategy for Sustainability Towards a Toxic-Free Environment. [Online]. Available: https://environment.ec.europa.eu/strategy/chemicals-strategy\_en.
- [5] J. Hollender, E. L. Schymanski, H. P. Singer, and P. L. Ferguson, "Non-target screening with high resolution mass spectrometry in the environment: Ready to go?" *Environmental Science & Technology*, vol. 51, no. 20, pp. 11505–11512, 2017, PMID: 28877430. DOI: 10.1021/acs.est.7b02184. eprint: https://doi.org/10.1021/acs.est.7b02184. [Online]. Available: https://doi.org/10.1021/acs.est.7b02184.
- [6] K. Arturi and J. Hollender, "Machine learning-based hazard-driven prioritization of features in nontarget screening of environmental high-resolution mass spectrometry data," *Environmental Science & Technology*, vol. 0, no. 0, null, 0, PMID: 37279189. DOI: 10.1021/acs.est.3c00304.

eprint: https://doi.org/10.1021/acs.est.3c00304. [Online]. Available: https://doi.org/10.1021/acs.est.3c00304.

## Appendix A

# **Appendix**



Eidgenössische Technische Hochschule Zürich Swiss Federal Institute of Technology Zurich

## **Declaration of originality**

The signed declaration of originality is a component of every semester paper, Bachelor's thesis, Master's thesis and any other degree paper undertaken during the course of studies, including the respective electronic versions.

respective electronic versions.					
Lecturers may also require a declaration of originality for other written papers compiled for their courses.					
I hereby confirm that I am the sole author of the in my own words. Parts excepted are correction	ne written work here enclosed and that I have compiled it ons of form and content by the supervisor.				
Title of work (in block letters):					
<b>Authored by</b> (in block letters): For papers written by groups the names of all authors are	required.				
Name(s):	First name(s):				
	agiarism described in the 'Citation etiquette' information				
<ul><li>sheet.</li><li>I have documented all methods, data and</li><li>I have not manipulated any data.</li></ul>	I processes truthfully.				
- I have mentioned all persons who were si	ignificant facilitators of the work.				
I am aware that the work may be screened ele	ectronically for plagiarism.				
Place, date	Signature(s)				

For papers written by groups the names of all authors are required. Their signatures collectively guarantee the entire content of the written paper.